BOSTON,
July 17,
2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a
biotechnology company pioneering the discovery and development of
oral, small molecule allosteric therapies targeting regulatory
sites on proteins referred to as "natural hotspots," today
announced it will present initial clinical data, with a focus on
safety, exposure, and pharmacodynamic measures, from the
monotherapy dose-escalation portion of the Phase 1 study of
HST-1011, an oral, selective inhibitor of Casitas B-lineage
lymphoma proto-oncogene (CBL-B), in a Proffered Paper oral
presentation at the European Society for Medical Oncology (ESMO)
Congress 2024, taking place September 13-17,
2024, in Barcelona,
Spain.
Presentation details are as follows:
Title: First-in-Human (FIH) Phase 1
Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with
Advanced Solid Tumors
Session Name: Proffered Paper session: Investigational
immunotherapy
Session Date and Time: Fri., Sep. 13,
2024, 16:00-17:30 CEST
Presentation Time: 16:50-17:00
CEST
Location: Burgos Auditorium – Hall 5, Fira Barcelona Gran
Via
Presentation Number: 991O
About HotSpot Therapeutics,
Inc.
HotSpot Therapeutics, Inc. is a clinical-stage
biotechnology company that is pioneering a new class of allosteric
drugs that target certain naturally occurring pockets on proteins
called "natural hotspots." These pockets are decisive in
controlling a protein's cellular function and have significant
potential for new drug discovery by enabling the systematic design
of potent and selective small molecules with novel pharmacology.
The Company's proprietary Smart Allostery™ platform combines
computational approaches and AI-driven data mining of large and
diverse data sets to uncover hotspots with tailored pharmacology
toolkits and bespoke chemistry to drive the rapid discovery of
novel hotspot-targeted small molecules. Leveraging this approach,
HotSpot is building a broad pipeline of novel allosteric therapies
for the treatment of cancer and autoimmune diseases. To learn more,
visit www.hotspotthera.com.
Investor & Media Contact:
Natalie Wildenradt
nwildenradt@hotspotthera.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-to-present-initial-first-in-human-phase-1-clinical-data-on-its-novel-cbl-b-inhibitor-hst-1011-at-esmo-congress-2024-302198838.html
SOURCE HotSpot Therapeutics